Investors have indicated they support Pfizer CEO Ian Read and his strategies despite a second failed attempt at a big tax inversion deal.
One day after the Pfizer deal to buy Allergan was officially terminated, Allergan announced a multibillion pact with Heptares Therapeutics for neurological disorders.
In a surprise move, the U.S. Treasury Department released a new set of rules to make it more difficult for U.S. companies to conduct so-called tax inversions.
Gilead Sciences struck a $1.2 billion deal to acquire Cambridge, Mass.-based Nimbus Apollo Inc. for its Acetyl-CoA Carboxylase (ACC) inhibitor program.
Gains full-rights to Padlock’s Protein/Peptidyl Arginine Deiminase (PAD) inhibitor discovery program Expands Bristol-Myers Squibb’s immunoscience pipeline with potentially transformational approach to treating rheumatoid arthritis and other autoimmune diseases March 23, 2016 06:59 AM Eastern Daylight Time NEW YORK & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) and Padlock Therapeutics, Inc. announced today that the […]
Newport Beach, CA — March 15, 2016 Glutenase for in-vivo gluten degradation is a leading candidate for celiac disease ImmunogenX™, a biopharmaceutical company focused on the diagnosis and treatment of autoimmune and gastrointestinal diseases, today announced that it has completed the acquisition of the non-cash assets of Alvine Pharmaceuticals, This includes the Latiglutenase (formerly […]
Teva Pharmaceutical Industries Ltd (TEVA.TA) has offered concessions to allay EU antitrust concerns over its $40.5 billion bid for Allergan’s (AGN.N) generics unit which will cement its position as the world’s largest generics drugmaker. “Commitments have been submitted and the new legal deadline is set on 10 March,” European Commission spokesman Ricardo Cardoso said […]
Avalanche Biotechnologies and Annapurna Therapeutics Announce Proposed Merger – Combined Scientific, Financial and Human Resources Will Support Robust Gene Therapy Pipeline Companies to Host Conference Call Today at 8:00 a.m. ET/ 5:00 a.m. PT MENLO PARK, Calif. and PARIS, Feb. 01, 2016 (GLOBE NEWSWIRE) — Avalanche Biotechnologies, Inc. (“Avalanche”) (Nasdaq:AAVL) and Annapurna Therapeutics SAS (“Annapurna”), […]
ABBOTT PARK, Ill. – Waltham, Mass.-based Alere Inc. (ABT)’s stock is up more than 45 percent following news of its acquisition by Chicago-based Abbott Laboratories (ABT) this morning. Alere’s stock is trading at $54.01 per share. Up $16.81 in pre-market sales. Abbott announced this morning it was acquiring Alere Inc. for $5.8 billion in an […]
Pershing Square’s Bill Ackman Writes Letter of Apology to Investors, Regrets Investing so Heavily into Valeant
In a 13-page letter to clients, Pershing Square Capital Management’s Bill Ackman apologized for the debacle of 2015 and, in a not-quite-a-mea-culpa, takes responsibility for some bad decisions. One of the key mistakes he takes credit for is not selling Valeant Pharmaceuticals International (VRX) stock when its share price rose over $200 in the summer. […]